IMFINZI® (durvalumab) granted Priority Review in the US for …
Dec 6, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & …
Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC …
Oct 23, 2024 · New preclinical data on PRMT5-MTA inhibitor program will also be presented. NEW YORK, NY, USA I October 23, 2024 I Schrödinger (Nasdaq: SDGR) today announced …
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial ...
Oct 21, 2024 · Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW171 in treatment of ovarian cancer, non-small cell lung cancer (NSCLC), and other mesothelin …
PipelineReview.com. Biopharmaceutical News & Clinical Trials
PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie …
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for …
Oct 12, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & …
Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine …
Oct 10, 2024 · GAITHERSBURG, MD, USA I October 9, 2024 I Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today …
PeptiDream Announces Second Internal Peptide …
Dec 14, 2024 · KAWASAKI, Japan I December 12, 2024 I PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter …
Tenaya Therapeutics Announces Updates on TN-201 Gene …
Oct 18, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & …
ESSENCE Phase 3 trial results demonstrating statistically significant ...
Nov 20, 2024 · The trial achieved both its primary endpoints, with semaglutide 2.4 mg demonstrating statistically significant and superior improvements in liver fibrosis with no …
Merck’s Investigational Zilovertamab Vedotin in Combination With …
Dec 9, 2024 · Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate. RAHWAY, NJ, USA I December 08, 2024 I …